EUCTR2021-003023-14-SE进行中（未招募）1 期
Pharmacokinetics of Cobitolimod Enemas in Participants with active Ulcerative Colitis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Willing and able to give written informed consent for participation in the study.
- •2.Male or female patient aged =18 years.
- •3.Established diagnosis of UC, with minimum time from diagnosis of at least 3 months before screening.
- •4.Moderate to severe active UC (disease should extend 15 cm or more above the anal verge) determined by a 3-component Mayo score of 5 to 9 with an endoscopic subscore =2 (in sigmoid or descending segments) assessed by the Investigator’s reading of the endoscopy, and with a stool frequency and rectal bleeding subscores each =1.
- •5.Clinically acceptable medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator.
- •6.Women only:
- •WOCBP must practice abstinence (only allowed when this is the preferred and usual lifestyle of the patient) or must agree to use a highly effective method of contraception with a failure rate of < 1% to prevent pregnancy (combined [oestrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD] or intrauterine hormone-releasing system [IUS]) from at least 4 weeks prior to dose to 4 weeks after last dose. Female patients must refrain from donating eggs from the date of dosing until 3 months after dosing with the IMP. Their male partner must agree to use a condom during the same time frame if he has not undergone vasectomy.
- •Women of non-childbearing potential are defined as pre-menopausal females who are sterilised (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone [FSH] 25-140 IE/L is confirmatory).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1. Suspicion of differential diagnosis such as Crohn’s enterocolitis, ischaemic colitis, radiation colitis, indeterminate colitis, infectious colitis, diverticular disease, associated colitis, microscopic colitis, massive pseudopolyposis or non-passable stenosis.
- •2. Acute fulminant UC, toxic megacolon and/or signs of systemic toxicity.
- •3. Have failed treatment with more than three advanced therapies (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab or tofacitinib) of two different therapeutic classes (anti-TNF, anti-integrins, anti-IL12/23, JAKinhibitors, or other approved advanced therapies for UC).
- •4. Have had surgery for treatment of UC.
- •5. History of malignancy, unless treated with no relapse of the disease and = 5 years since last treatment (cured) or treated (cured) basal cell or squamous cell in situ carcinoma.
- •6. Serious known active infection including history of latent or active tuberculosis, documented history of past or current tuberculosis, or living with or having frequent close contact with people with active tuberculosis or with a positive tuberculosis test according to current regulations for 12 weeks preceding randomisation. Serious infections include, but is not limited to, HIV, hepatitis B, or hepatitis C infections.
- •7. Gastrointestinal infections including positive Clostridium difficile stool assay (laboratory reports must be available in accordance with normal clinic practice, to confirm that the current episode of disease exacerbation is not due to infection).
- •8. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant’s ability to participate in the study.
- •9. Concomitant or planned treatment with cyclosporine, methotrexate, tacrolimus, or advanced therapies such as infliximab, adalimumab, golimumab, vedolizumab,ustekinumab or tofacitinib, or similar immunosuppressants and immunomodulators at enrolment.
- •Any prior treatment with such drugs must have been discontinued at least 8 weeks prior to Visit 1 (except for ustekinumab, which must have been discontinued at least 12 weeks prior to Visit 1) or have non-measurable serum concentration levels.
- •10. Treatment with rectal GCS, 5-ASA/SP or tacrolimus within 2 weeks before Visit 1.
- •11. Long-term treatment (>14 days) with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to Visit 1 (one short treatment regimen for antibiotics, occasional use of NSAIDs and low dose NSAIDs as prophylactic therapy is allowed).
- •12. Females who are lactating or have a positive serum pregnancy test at Visit 1.
- •13. Any planned major surgery within the duration of the study.
- •14. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1.
- •15. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
- •16. Investigator considers the participant unlikely to comply with study procedures, restrictions and requirements.
研究者
相似试验
Unknown
1 期
Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative ColitisUlcerative ColitisNCT05404074InDex Pharmaceuticals6
已完成
不适用
Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic studyPediatric patients infected with multi-drug resistant gram negative bacteria who need to receive intravenous colistincolistin population pharmacokineticspediatricMDROsTCTR20180526001Principal investigator
进行中（未招募）
1 期
Pharmacokinetic/pharmacodynamic aspects of colistin intravenous administration in critically ill patients suffering from hospital infections caused by multi-antibiotic-resistant germs and receiving continuous renal replacement therapy.Critically ill patients suffering from hospital infections caused by multi-antibiotic-resistant germs and receiving continuous renal replacement therapy.MedDRA version: 20.0Level: PTClassification code 10053840Term: Bacterial sepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-001019-95-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE20
进行中（未招募）
不适用
Pharmacokinetic and colimicine (ColistinaR) concentrations in broncho alveolar lavage in patients affected by pulmonary infections caused by Gram - bacteria. - NDEUCTR2007-005045-38-ITOSPEDALE POLICLINICO S. MATTEO
进行中（未招募）
不适用
Pharmacokinetics of colistimethate and colistine after a 60 minutes intravenous infusion of colistimethate 1 million UI (80 mg) in 12 healthy volunteersEUCTR2007-003092-39-FRCHU DE POITIERS